Author: Michele Neisemann

Media Releases

BioCurate strikes MOU with Novartis, eyes more ‘Big Pharma Deals’

Comment

BioCurate strikes MOU with Novartis, eyes more ‘Big Pharma Deals’

Author

Date

Ben Potter, Australian Financial Review

November 02, 2018

BioCurate, a joint venture of Monash and Melbourne universities for early stage commercialisation of pharmaceutical research, has struck an agreement with global pharmaceuticals giant Novartis to share research and accelerate discoveries of new drugs.

Glenn Begley, chief executive of BioCurate, said the memorandum of understanding would cover a full range of research from the two universities, which snare more than 40 per cent of federal biomedical research grants between them, with an emphasis on areas of special interest to Novartis, such as oncology drugs.

Dr Begley, who started at BioCurate in January after 20 years in the US, said the deal was not exclusive and BioCurate would be free to strike similar arrangements with other pharma giants who are approaching the organisation.

“One of the things that’s been really exciting about BioCurate is the interest that has come from international pharmaceutical companies and VC firms around the world,” he told The Australian Financial Review.

Read more here:  https://www.afr.com/news/biocurate-strikes-mou-with-novartis-eyes-more-big-pharma-deals-20181031-h17cjk

Return to News
Share
RELATED
Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery
Read more
New Staff Appointment – Dr Lorna Mitchell
Read more
Media Releases

Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery

Comment

Novartis and BioCurate announce first collaboration to accelerate early stage drug discovery

Author

Date

BioCurate

October 31, 2018

Novartis is the first global biopharma to enter into a Memorandum of Understanding (MoU) with BioCurate Pty Ltd to collaborate on early stage drug discovery projects with a view to provide expert industry-focused scientific advice and expertise to BioCurate.
  • The collaboration provides a valuable opportunity to identify and translate innovative research from two of the world’s top ranked1 universities for biological sciences – Monash University and the University of Melbourne
  •  While Novartis is Australia’s largest sponsor of clinical trials2, the MoU with BioCurate emphasises an additional focus of identifying early stage innovation and academic research which addresses unmet patient needs

Melbourne, October 31, 2018 – The Australian biomedical research company BioCurate Pty Ltd and Novartis today announced that they will collaborate on early stage drug discovery projects that have potential to address an unmet need.

This collaboration marks BioCurate’s first with the global pharmaceutical industry.

Head of Strategic Partnerships at Novartis, Brett Roberts, said the collaboration with BioCurate is a unique opportunity to work with Monash University and the University of Melbourne on new innovative medicines.

“We are very excited to be able to bring together the global scientific and technical expertise of researchers at the Novartis Institute of Biomedical Research (NIBR) with BioCurate’s expertise in curating and translating early stage science into development ready Australian research projects,” said Mr Roberts.

BioCurate CEO, Dr C. Glenn Begley said the company recognised the importance of early engagement with a range of leading industry partners to ensure new drug development programs are informed and aligned with addressing unmet patient and market needs.

“We are delighted to collaborate with Novartis – a first-class innovator with considerable expertise and infrastructure that can potentially support Australia’s drug discovery and development capabilities,” Dr Begley said.

“We are hopeful this collaboration will ultimately lead to better health outcomes for the global community and continue to build Australia’s expanding innovation economy.”

Dr Begley said the collaboration with Novartis marks the first in a number of similar arrangements currently under discussion with other potential industry partners.

BioCurate, a joint venture of Monash University and the University of Melbourne, supported by the Victorian State Government, operates independently and is housed in the internationally renowned ‘Parkville Precinct’ in Melbourne, a cluster of 30 world-class hospitals, research institutes, teaching and biotech organisations employing approximately 10,000 researchers.

“BioCurate is uniquely positioned to lead the establishment of a number of international industry experts who are able to provide invaluable scientific advice, commercial insight and partnering opportunities to BioCurate and Australia’s medical research sector,” Dr Begley said.

Novartis Australia Chief Scientific Officer, Dr Simon Fisher, said it was a unique opportunity to leverage an internationally experienced team dedicated to rigorous analysis of local science to address unmet patient needs as well as commercial potential.

“This collaboration opens the door to overcome barriers that limit the translation and commercialisation of early stage research progressing to new medicines and providing benefits to patients,” Dr Fisher said.

“We know the research undertaken in Australia is as good as anything globally, so this is an opportunity to help advance the outputs of Australian science. We hope that collaborations of this kind will benefit Australian science and patients.”

Whilst the therapy focus areas of the BioCurate/Novartis partnership are yet to be confirmed, the focus will be to triage and prioritise the highest quality early stage research opportunities from BioCurate’s review of a promising portfolio of projects.

References

  1. The Times Higher Education World University Rankings 2018 (Life Sciences) https://www.timeshighereducation.com/world-university-rankings/2018/subject-ranking/life-sciences#!/page/0/length/25/subjects/3051/sort_by/rank/sort_order/asc/cols/stats (Accessed 24 October 2018)
  2. AusTrade Clinical Trials Capability Report 2018 https://www.austrade.gov.au/news/latest-from-austrade/2018/new-report-spotlights-australias-capability-in-clinical-trials (Accessed 24 October 2018)

ENDS

 

About BioCurate

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development.  BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public good routes. The Company’s vision is to be a recognised global leader in the translation of basic medical research into human therapeutics. For more information, please visit https://www.biocurate.com
Twitter: @biocurate
LinkedIn: https://www.linkedin.com/company/biocurate/

 

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

 

About Novartis Institutes for BioMedical Research

The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organisation of Novartis. With an ongoing focus on diseases for which medical needs remain unmet, scientists and physicians at NIBR are dedicated to ensuring that Novartis maintains its strong pipeline. NIBR has sites in Basel, Switzerland; Shanghai, China; Cambridge, Massachusetts; and three other US locations.

 

BioCurate Pty Ltd Media Contact:

Linda Peterson
Chief Operating Officer
M: +61 419 320 435
E: l.peterson@biocurate.com

 

Novartis Australia/NZ Media Contact:

Peter Murphy
Director, Public Affairs and Communications
M: 0423 444897
peter.murphy@novartis.com

Return to News
Share
RELATED
BioCurate launches first round of project investments
Read more
New Staff Appointment – Dr Lorna Mitchell
Read more

This collaboration opens the door to overcome barriers that limit the translation and commercialisation of early stage research progressing to new medicines and providing benefits to patients.

Dr Simon Fisher
Novartis Australia Chief Scientific Officer
Media Releases

New Staff Appointment – Dr Lorna Mitchell

Comment

New Staff Appointment – Dr Lorna Mitchell

Author

Date

BioCurate

October 22, 2018

BioCurate is very pleased to announce Dr Lorna Mitchell’s appointment as Senior Project Leader.

BioCurate is focused on turning discoveries into therapeutics, and is building a team of highly-experienced individuals capable of working collaboratively to ensure the company’s success.

Dr Mitchell brings a depth and breadth of scientific expertise and 17 years of international drug discovery experience in the biotech and pharmaceutical industry.  With particular strengths in medicinal chemistry, Lorna brings a complementary and highly valuable skill-set to the BioCurate team as the company progresses the development plans for its first projects.  Together with her colleagues, Lorna will lead and manage the development of the BioCurate project portfolio from initial academic interaction through oversight and delivery of specific project milestones.  As Senior Project Leader she will work closely with the inventors, support the Universities to help build their capability in translational research and liaise closely with other key players required for the successful commercial development of projects.

Dr Mitchell has experience across multiple therapeutic areas including dermatology, antivirals, CNS and oncology.  She has had responsibility for leadership of diverse chemistry & cross-­disciplinary teams.  Lorna has been directly involved in delivery of 9 drug candidates to the clinic and in validation, or timely no-­go decisions, on multiple new targets and projects.

We are delighted that she has decided to join the BioCurate team!

Dr Lorna Mitchell will commence in her new role on 22 October 2018.

Return to News
Share
RELATED
The Academic Insider – Stories from flirting with the ‘Dark Side’
Read more
BioCurate launches first round of project investments
Read more
insight

The Academic Insider – Stories from flirting with the ‘Dark Side’

Comment

The Academic Insider – Stories from flirting with the ‘Dark Side’

Author

Date

BioCurate

September 26, 2018

Dark side (noun): the missing link between academic research and achieving impact

‘I think academic researchers are mindful of the fact that they need to translate their discoveries. But how to actually go about doing that remains somewhat of a black box,’ says Dr Natalie Borg. This sentiment is shared by many biomedical researchers and reflects the knowledge and experience gap that exists between a basic discovery and translation of research into something that has real impact.

In the academic environment, because of the lack of expertise and funding, this gap is known as “the valley of death.” Yet this valley is routinely traversed within industry. It is therefore essential to demystify this process, and provide the resources and know-how that exists within industry to bridge this gap if we are to realise the full potential of academic scientific discoveries.

The challenge, however, facing the translation of academic science to achieve impact for human health is demonstrated by the increasing cost of drug development over recent years. According to the Tufts Center for the Study of Drug Development, during the 1990s, the development of a new drug took an average of 8 years with costs up to $USD802 million. Today, that figure stands at 15 years and $USD2.6 billion, in spite of dramatic advancements in knowledge and technology. This quantifiable inflation in cost and time has driven a greater outward research focus of industry as it seeks to harness academic advances. BioCurate was specifically created to foster a stronger understanding and collaboration between academia and industry – to bridge the academic valley of death.

Professor Dale Godfrey and Dr Natalie Borg, two researchers who have maintained long-running conversations about their respective projects with the BioCurate team, understand this problem all too well. Professor Dale Godfrey is currently an NHMRC SPRF in the Department of Microbiology and Immunology at the University of Melbourne and Immunology Theme Leader at the Peter Doherty Institute for Infection and Immunity; and Dr Natalie Borg is an ARC Future Fellow and lab head based in the Department of Biochemistry and Molecular Biology at Monash University. While each are at different stages of their career and commercialisation journeys, both have come to realise they no longer need to view their research and achieving its commercial potential as separate endeavours.

With the uncertain path to commercialisation and the publish or perish mentality firmly entrenched in academia, “research-translation” can simply become an empty cliché. Both Dale and Natalie have had indirect interactions with the world of commercialisation throughout their academic careers. Dale completed his postdoctoral research in the United States, in an academic environment that was funded by industry. He recalls, ‘there was a friendly lawyer who would wander around the labs, asking about any new findings that could be patentable.’ He has also consulted for and embarked on small collaborations with several companies. Natalie undertook her PhD in a lab and at an institute that was heavily involved in the development of the influenza drug, Relenza®. This exposed her to the research path that led to commercialisation. ‘Through absorption, I learnt a lot and found the process quite inspiring,’ says Natalie.

In spite of this early exposure, for both Dale and Natalie, working in the highly competitive research grant-funded academic environment in Australia meant that the need to present and publish research has taken priority over advancing research in collaboration with industry. Combined with limited information and few examples, it has been difficult for researchers to seriously contemplate commercialisation. Buzzwords such as commercialise and translate are often bandied about, but tangible means to progress such aspirations are limited. Today, advice on how to pursue this pathway is increasingly accessible and opportunities are becoming more apparent, sparking a shift in the mindset of many academic scientists.

BioCurate was designed to help facilitate this change in attitudes through education and true partnership, allowing academic scientists to explore the potential avenues to effect impact on human health. ‘It just wasn’t standard thinking. When faced with exciting results, I would think about how good it will be to present them at an upcoming conference, how to turn them into a publication or how I’ll use them for a grant application,’ states Dale. Things are beginning to change. ‘Now I’m also thinking about whether new results we have in the lab might have commercial and clinical potential by way of industry engagement.’ The guidance BioCurate has provided to Dale has given him a clearer view of the industrial therapeutic landscape, the opportunities and options therein, and the potential courses of action. It has helped him understand the best way to navigate sensitive areas of confidentiality and how this path can be managed in the context of other academic pressures.

For Natalie, who co-leads one of the six drug discovery projects that were selected for BioCurate’s first round of project investments, the application process was, in and of itself, enlightening. ‘It was the first time I really had to think about my research assets, who am I competing with, what is on the market?’ said Natalie. Currently, BioCurate’s support has mobilised her science, providing her the resources to push forward, as well as advice on finding the balance between publishing data and maintaining the commercial viability of her research. Not only that, but Natalie has found the chance to tap into the expertise of the BioCurate team to be hugely beneficial, educational – and enjoyable! Through this, she is learning a new vocabulary – one that is aiding her in conversing with industry. Her deeper understanding of the complexities and nuances of commercialisation is facilitating this journey.

BioCurate operates in the under-resourced yet highly critical early phases of new drug development. This phase represents an unmissable opportunity to grow greater links and collaboration between academia and industry and by doing so, will improve the development of potential treatments, for small molecules and biologics, across different therapeutic areas. BioCurate bridges this gap by providing the critical ‘missing link’ – industry experience and clear commercial focus; targeted funding and project management; mentoring and support – that will enable researchers to maximise the impact of their research.

Return to Insight
Share
RELATED
BioCurate launches first round of project investments
Read more
For Researchers
Read more
Media Releases

BioCurate launches first round of project investments

Comment

BioCurate launches first round of project investments

Author

Date

BioCurate

July 31, 2018

BioCurate Pty Ltd has achieved an important milestone with investments in six early drug discovery projects from research groups at The University of Melbourne and Monash University announced today. These projects represent the first tranche of investments for BioCurate.

BioCurate’s CEO, Dr Glenn Begley said “I am delighted that BioCurate has taken this important next step. We are building on the combined research strength of these two outstanding Australian universities, accelerating and strategically guiding these high value projects to give them the best possible chance of commercial and clinical success.”

All of the projects have compelling clinical and commercial reasons to support their early investment and development. Each addresses an important unmet clinical need, adopts a novel approach and targets potential global markets.

BioCurate is pleased to have formally commenced its core business of targeting the critical early phases of drug development. The Company will take on several more projects throughout 2018 and will work across different therapeutic areas and modalities including small molecules, biologics and antibodies. Collaboration, cooperation and commercial rigour to achieve scale at the international level, will be the hallmarks of the Company’s approach

The development plan for each project identifies key ‘Go/No-Go’ gates with an early and consistent focus on ensuring the essential commercial imperatives of reproducible data and a clear intellectual property position.

Working closely and collaboratively with each of the project’s investigators and University colleagues, BioCurate is providing ‘on the ground’ expertise and mentoring in drug development and commercialisation, funding and project management. This, coupled with BioCurate’s extensive international industry experience in drug development and biopharmaceutical and investment networks, will boost the opportunity for these, and future, projects to undergo successful translation.

The successful investigator’s and their inaugural projects to enter BioCurate’s project pipeline are:

  • Dr Glen Carter and Prof Jonathan Baell – A novel class of antibiotics
  • Dr Natalie Borg and Prof David Jans – A new target for both viral infection and cancer
  • Profs Charles Mackay, Dr Remy Roberts and Prof Mark Sleeman – A novel therapeutic for cancer
  • Prof Rob Widdop, Prof Mibel Aguilar and Dr Mark Del Borgo – Anti-fibrotic therapy
  • Prof Ray Norton – A new treatment for autoimmune diseases
  • Dr Sheena McGowan and Prof Peter Scammells – Novel therapeutics for infection and cancer

About BioCurate Pty Ltd

BioCurate is a joint venture of the University of Melbourne and Monash University, supported by the Victorian State Government. Announced in June 2016, its founding universities are placed in the world’s top ten in the therapeutic areas of immunology, oncology, paediatrics, neurosciences, and infectious diseases.

BioCurate aims to be a recognised global leader in the translation of basic medical research into human therapeutics.

The Company offers a new model, designed to address the key challenges in early stage drug development, and will focus on those stages of development before a project is attractive to the biomedical industry or venture capital funds. Its purpose is to increase the number, quality and rate of translation of new drug discoveries into medically sound and commercially attractive, investable projects.

BioCurate is also committed to helping develop the broader ecosystem and growing the local pipeline of high quality preclinical candidates for the bio-pharmaceutical industry. Increasing the number of ‘investment-ready’ projects will grow the Victorian and Australian biotech sector by attracting global interest in partnering and investment

BioCurate is owned jointly by the Universities and is independently governed and operated with the Hon John Brumby AO as Chair and Dr C.Glenn Begley as CEO.

Quotes from Monash University and the University of Melbourne:

Monash University’s Deputy Vice-Chancellor and Vice-President (Enterprise), Ken Sloan, welcomed the announcement. “BioCurate’s critical role as a catalyst across Universities, government and industry helps to accelerate improvements to the health of the community” Mr Sloan said. “We are delighted therefore to see the first cohort of research projects enter BioCurate’s pipeline for investment and development.”

Doron Ben-Meir, Vice-Principal (Enterprise) at the University of Melbourne, said “The unprecedented vision of BioCurate – to combine seasoned pharmaceutical industry professionals with our world class research substrate – is realising its first steps. It’s very exciting to see the first cohort of projects. We look forward to their continued development and to seeing many more promising candidates emerge from our growing pipeline of exceptional research.”

Quote from the Victorian Government Minister for Innovation and the Digital Economy, Philip Dalidakis:

Minster for Innovation and the Digital Economy Philip Dalidakis said “The Victorian Government is proud to support the early-stage drug development research lead by Melbourne and Monash Universities, whose combined expertise in the areas of pharmacology, immunology, neurosciences, and cardiology see them ranked among the world’s best. Congratulations to the successful researchers, whose projects have the potential to cure terrible diseases and improve patient care both across Victoria and around the world.”

ENDS

For more information on BioCurate: www.biocurate.com

Dr Begley is available for interviews.

 

 

Media contacts

Linda Peterson
Chief Operating Officer and Company Secretary
Tel:  +61 419 320 435
E:  l.peterson@biocurate.com

Twitter: @biocurate
LinkedIn:https://www.linkedin.com/company/biocurate/

Return to News
Share
RELATED
BioCurate and Neurosciences Victoria enter into a Memorandum of Understanding
Read more
2017 Annual Report
Read more

BioCurate’s critical role as a catalyst across Universities, government and industry helps to accelerate improvements to the health of the community.

Ken Sloan
Monash University’s Deputy Vice-Chancellor and Vice-President (Enterprise)
News

BioCurate and Neurosciences Victoria enter into a Memorandum of Understanding

Comment

BioCurate and Neurosciences Victoria enter into a Memorandum of Understanding

Author

Date

BioCurate

May 14, 2018

BioCurate is excited to announce a new collaboration with Neurosciences Victoria (NSV). The two organisations will work together to identify neuroscience project opportunities that may be of interest to BioCurate. This affiliation will provide a tremendous opportunity to help researchers build their translational capability and provide them with another avenue for review of projects as well as increasing deal flow across the neuroscience sector. Both BioCurate’s founding universities, The University of Melbourne and Monash University, are members of NSV.

Dr C Glenn Begley, BioCurate’s Chief Executive Officer, is very happy to be collaborating with NSV:

“Through a strong alliance of shared goals, we look forward to seeing great outcomes as research comes to fruition across the neuroscience field”, said Dr Begley.

Dr Anthony Filippis, NSV’s Chief Executive Officer, is delighted to be affiliated with BioCurate:

“We look forward to working with BioCurate in building and augmenting relationships and collaboration within the Victorian neuroscience research community”, said Dr Filippis.

 

Return to News
Share
RELATED
2017 Annual Report
Read more
BioCurate CEO Dr Glenn Begley presents at Harvard and Stony Brook Universities
Read more

Through a strong alliance of shared goals, we look forward to seeing great outcomes as research comes to fruition across the neuroscience field

Dr C Glenn Begley
CEO, BioCurate
Annual Reports

2017 Annual Report

Comment

2017 Annual Report

Author

Date

BioCurate

February 21, 2018

BioCurate Pty Ltd ABN: 67 614 173 278 Annual Report for the year ended 31 December 2017

The 2017 Annual Report focuses on an exciting start BioCurate has made in its quest to develop new medicines, and provides a glimpse of what 2018 has in store.

BioCurate 2017 Annual Report

 

Return to News
Share
RELATED
BioCurate 2018 Annual Report
Read more
BioCurate CEO Dr Glenn Begley presents at Harvard and Stony Brook Universities
Read more
News

New staff appointments

Comment

New staff appointments

Author

Date

BioCurate

November 02, 2017

Dr Glenn Begley is very pleased to advise of the following senior appointments to the positions of Chief Operating Officer and Senior Project Leader (two appointments).

These appointments signal the very important next stage for BioCurate. The Company has now established its operations and will soon be taking on its first projects. BioCurate will provide the management, commercial focus, international expertise and funding necessary to boost their successful translation and commercialisation.

Chief Operating Officer and Company Secretary

Linda Peterson has extensive experience across the academic, not for profit and corporate life sciences sector and has held positions in medical research, R&D, business management and executive leadership. Linda has been the Interim Chief Operating Officer and Company Secretary for BioCurate since July 2016. Working closely with the Board and University partners, Linda has been responsible for leading and managing all aspects of the set-up and independent operations of the company, including establishing the office facilities and back-office support arrangements, governance processes, operational systems and policies, communications and the recruitment of key staff. Immediately prior to joining BioCurate, Linda was the Executive Manager for the Bionics Institute and CEO of Bionic Enterprises Pty Ltd. Linda’s qualifications include a Bachelor of Science and post graduate qualifications in business administration.
Linda commenced in her new position of Chief Operating Officer and Company Secretary on 1 October, 2017.

Senior Project Leaders

Two outstanding and highly experienced professionals, Dr Catherine Drinkwater and Dr Eric Hayes have been appointed to the positions of Senior Project Leader. Their combined breadth of scientific expertise and project management experience bring valuable skills to the company as it prepares to take on its first projects. Drs Drinkwater and Hayes will lead and manage the development of the BioCurate project portfolio from initial academic interaction through oversight and delivery of specific project milestones. The Senior Project Leaders will work closely with the inventors, support the Universities to help build their capability in translational research and liaise closely with other key players required for the successful commercial development of projects.

Dr Catherine Drinkwater has extensive experience in both academic research and industry drug development. Following completion of her PhD at the Howard Florey Institute, Cathy went on to postdoctoral fellowships at Stanford University School of Medicine (California) and the Walter and Eliza Hall Institute of Medical Research. Since then she has worked in the commercial sector, as Principal Scientist at AMRAD Corporation (later Zenyth Therapeutics) and Project Manager at CSL, and at the research/industry/education “interface” with the Cancer Therapeutics CRC. During that time, she was responsible for leading and managing several early discovery and development projects, working with research teams to enhance their collaborative efforts and facilitate the timely delivery of their outcomes. Cathy has experience in a range of therapeutic areas including endocrinology, neurobiology, oncology, immunology and inflammation. Dr Drinkwater will commence in her new role on 13 November, 2017.

Dr Eric Hayes has academic, commercial drug development and pharmaceutical R&D support services experience, spanning over 25 years, in Europe, North America, Asia and Australia. Eric completed undergraduate and post-graduate studies in medical pharmacology at the University of British Columbia and the National University of Singapore. As a scientist, Eric has deep experience in preclinical drug development and supportive assay/model development. He has a breadth of therapeutic area experience including CNS, respiratory, metabolic, infectious diseases, cardiovascular and genitourinary diseases. As an entrepreneur, he has assisted academic and commercial individuals and institutions with discovery, development and commercialization of a variety of life-sciences technologies with a strong focus on human therapeutics development.  Dr Hayes will commence in his new role in early January, 2018.

Return to News
Share
RELATED
BioCurate CEO Dr Glenn Begley presents at Harvard and Stony Brook Universities
Read more
BioCurate enters into a commercial services relationship with the Walter and Eliza Hall Institute of Medical Research (WEHI)
Read more
News

BioCurate CEO Dr Glenn Begley presents at Harvard and Stony Brook Universities

Comment

BioCurate CEO Dr Glenn Begley presents at Harvard and Stony Brook Universities

Author

Date

BioCurate

July 07, 2017

Dr Glenn Begley gave a presentation at Harvard Medical School on 27 June. Around 200 students, postdocs and senior members of the Faculty attended Dr Begley's thought provoking and entertaining talk on the problems with reproducibility in science. Afterwards, a group joined Dr Begley for a Q&A over lunch.

Dr Begley was also the keynote speaker at the US National Directors of Graduate Studies in Pharmacology and Physiology (NDOGS) at Stony Brook University on 29 June 2017.  This is the annual meeting of the Directors and members of the FDA.  Following the presentation Dr Begley participated in a panel to continue discussions on what should be encompassed in their training programs with one of the NIH attendees.

Return to News
Share
RELATED
BioCurate enters into a commercial services relationship with the Walter and Eliza Hall Institute of Medical Research (WEHI)
Read more
CEO appointed
Read more
News

BioCurate enters into a commercial services relationship with the Walter and Eliza Hall Institute of Medical Research (WEHI)

Comment

BioCurate enters into a commercial services relationship with the Walter and Eliza Hall Institute of Medical Research (WEHI)

Author

Date

BioCurate

June 14, 2017

BioCurate is a joint venture of the University of Melbourne and Monash University, supported by the Victorian State Government. This bold and important collaboration underpins BioCurate’s aim to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound, commercially attractive, investable projects.

Last month Dr C. Glenn Begley returned from the USA to Melbourne and commenced as BioCurate’s CEO, building on a distinguished career as haematologist, oncologist and biotech CSO. Last week BioCurate officially opened its new premises at 407 Royal Parade.

BioCurate brings a commercial skill-set and extensive global industry experience to this joint venture. It is recognized that in order to achieve sector-wide change, scale and international partnering, there will be a need, over time, to engage more broadly with the commercial development of Melbourne’s life-sciences sector.

BioCurate is pleased to announce that as a first step towards this broader sector engagement, BioCurate has entered into a Commercial Services Agreement with WEHI, the Department of Medical Biology in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.

This Agreement covers the provision by BioCurate to WEHI for some specialist commercialization advice and contains all the standard commercial clauses relating to confidentiality and conflict of interest. The Board has determined that this advice will be provided by BioCurate’s CEO and will comprise around 2-4 days per month.

Dr Begley is a full-time employee of BioCurate with the requirements of the Company and its University Shareholders being his highest priority. Building on Dr Begley’s appointment, the Company will attract additional capability and continue to build expertise specifically targeted at early drug development.

BioCurate is committed to building on the combined research strengths of its University Shareholders to make transformational drug candidates become a reality.

Return to News
Share
RELATED
CEO appointed
Read more
$10m to accelerate drug development
Read more